Kadcyla | search
Click here to view Kadcyla news from 60+ newspapers.
Bookmark or Share- KADCYLA® (ado-trastuzumab emtansine) in HER2+ Breast CancerKADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin ®) and a taxane.
- Trastuzumab emtansine (Kadcyla) - Cancer Research UKTrastuzumab emtansine is a type of targeted cancer drug. It is also known as Kadcyla. You pronounce it as tras-too-zoo-mab em-tan-seen. Trastuzumab emtansine is a combination of the drug trastuzumab (also known as Herceptin) and a chemotherapy drug called emtansine. It is a treatment for HER2 positive breast cancer.
- Trastuzumab emtansine (Kadcyla®) | Macmillan Cancer SupportTrastuzumab emtansine may be used when: cancer cells are still in the body after chemotherapy and surgery. the cancer has spread or come back after treatment. Trastuzumab emtansine is not the same as trastuzumab or trastuzumab deruxtecan. We have separate information about trastuzumab.
- What is KADCYLA® (ado-trastuzumab emtansine) for MBC?Who is KADCYLA for? KADCYLA is a prescription medicine used to treat HER2+ breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane.
- Trastuzumab emtansine - WikipediaTrastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1.
More
